Introduction
The ability to precisely manipulate a DNA sequence of interest in living cells can illuminate the function of genes and regulatory sequences and has the potential to enable treatments for human genetic diseases. Targeting a single gene within a vast genome, however, has proven to be a substantial challenge. The use of programmable nucleases to introduce double-stranded breaks at specified locations in a genome greatly increases our ability to make precise and efficient genetic modifications. Following double-stranded DNA cleavage, endogenous cellular DNA repair processes can lead to either error-prone non-homologous endjoining (NHEJ) (Lukacsovich et al., 1994; Rouet et al., 1994) , typically resulting in disruption of the target gene, or homology-directed repair (HDR) using an exogenous DNA template (Choulika et al., 1995; Rouet et al., 1994) , resulting in the replacement of the original DNA sequence with a new variant ( Figure 1A ). While technologies such as meganucleases were first discovered in the 1980s, difficulties in reprogramming these proteins to target-specific DNA sequences limit their usage (Paques and Duchateau, 2007) . Extensive alteration of a large number of amino acids are required to reprogram meganucleases, and iterative rounds of in vitro selections have often been used to engineer the protein to a given target (Takeuchi et al., 2014) . More recently, meganucleases have also been fused to TALE proteins to improve activity by addressing the TALE to the DNA region adjacent to the meganuclease cut site (Boissel et al., 2014) .
ZFNs and TALENs were the first two widely used programmable DNA-cleaving proteins. Both proteins rely on protein-DNA interactions arising from concatemeric Cys 2 -His 2 zinc-finger domains or TALE repeat domains, respectively. The Cys 2 -His 2 zinc-finger domain is one of the most common DNA-binding motifs in eukaryotes. Consisting of 30 amino acids in a conserved b-b-a configuration, several of these amino acids contact a total of three base pairs in the major groove of DNA, resulting in the three-nucleotide specificity of a zinc-finger domain (Lee et al., 1989; Miller et al., 1985; Parraga et al., 1988; Pavletich and Pabo, 1991) (Figure 1B ). Engineered proteins containing a string of zinc-finger domains connected by a linker sequence recognize DNA sequences 9-18 bp in length and represented the first widely used programmable DNA-binding proteins (Kim and Pabo, 1998; Liu et al., 1997) . Fusing these proteins to the FokI endonuclease (Bitinaite et al., 1998; Li et al., 1992) results in a zinc-finger nuclease (ZFN) (Kim et al., 1996) , an artificial enzyme that induces double-stranded DNA cleavage at a specified location in the genome.
Found naturally in the plant pathogenic bacteria genus Xanthomonas, TALE proteins contain a repeating array of 33-to 35-amino acid domains that each recognize a single DNA base pair ( Figure 1C ). Two amino acids, the repeat-variable di-residue (RVD), determine the DNA base specificity of each TALE domain (Boch et al., 2009; Deng et al., 2012; Mak et al., 2012; Moscou and Bogdanove, 2009) . Like zinc fingers, TALE repeats can be linked together in a modular fashion to program the recognition of long contiguous DNA sequences. Also similar to ZFNs, TALENs consisting of the fusion of FokI with a DNA-binding TALE repeat array allow double-stranded DNA cleavage at sites specified by the TALE protein (Christian et al., 2010; Li et al., 2011; Miller et al., 2011) . Due to the base-specific interactions of each TALE domain, TALENs have also been shown to be sensitive to cytosine methylation. Thus, along with the code for the unmodified bases A, T, G, and C, a different code for 5-methylcytosine (5mC) was also created and validated (Valton et al., 2012 (A) Once a programmable nuclease catalyzes double-stranded DNA cleavage, endogenous cellular non-homologous end-joining (NHEJ) or homology-directed repair (HDR) processes mediate DNA modification at the cleaved locus. While NHEJ yields small, random insertions or deletions (indels) at the cleavage site, HDR uses a separate single-or double-stranded DNA molecule as a template for the precise replacement of bases spanning the site of cleavage. (B) Zinc-finger nucleases contain repeats of zincfinger domains, each of which recognizes 3 bp of DNA. By fusing the DNA-binding domain to a FokI nuclease, a dimeric ZFN recognizes and cleaves DNA containing adjacent left and right half-sites. (C) TALENs consist of an array of 33-to 35-amino acid TALE domains fused to FokI nuclease. DNA specificity is determined by two amino acids, known as the repeat-variable di-residues (RVDs), within each TALE domain. By simply linking TALE modules together, TALENs can be programmed to recognize virtually any DNA sequence. Like ZFNs, TALENs are designed to recognize a left and right half-site. Upon DNA binding, FokI domain dimerization enables double-stranded DNA cleavage. (D) The CRISPR-Cas9 system is an RNA-programmed endonuclease. The guide RNA (gRNA) contains both the sequence necessary to bind to the Cas9 protein and a ''spacer'' sequence that binds to the target DNA following Watson-Crick base-pairing rules. By altering the spacer sequences in the gRNA, Cas9 can be targeted to virtually any DNA sequence that contains a short protospacer adjacent motif (PAM) downstream of the DNA target. The most commonly used S. pyogenes Cas9 makes a doublestranded cut 3-4 bp away from the PAM as indicated by the arrowheads. are able to target virtually any DNA sequence (Cermak et al., 2015; Reyon et al., 2012; Zhang et al., 2013) . These advances have also enabled the construction of TALEN libraries, such as one targeting 18,740 human protein-coding genes, for use in screening studies to identify genes associated with phenotypes of interest . Obligate heterodimeric ZFNs and TALENs have also been engineered to improve specificity. Whereas wild-type FokI can form homodimers and cleave DNA, mutations within the dimer interface can prevent undesired homodimerization. Heterodimeric TALENs have been found to induce on-target mutations with frequencies comparable with their homodimeric counterparts but with better toxicity profiles (Cade et al., 2012) .
The recent development of the CRISPR-Cas9 system further increased the accessibility of programmable nucleases. At the heart of type-II CRISPR systems, natural bacterial immune systems that evolved to destroy foreign DNA, is Cas9 an RNA-programmed DNA nuclease ( Figure 1D ). The native type-II CRISPR system requires the Cas9 protein and two short pieces of RNA, the CRISPR RNA (crRNA) and the trans-activating crRNA (tracrRNA), for RNA-guided DNA cleavage (Deltcheva et al., 2011; Gasiunas et al., 2012; Jinek et al., 2012) . The crRNA contains the ''spacer,'' a short segment of RNA that complements the target DNA sequence and guides the Cas9 protein to the target locus through base pairing with one of the DNA strands. By changing the spacer sequence, Cas9 can be directed to many DNA sequences, with the main requirement being a conserved protospacer adjacent motif (PAM) sequence downstream of the target DNA site (Gasiunas et al., 2012; Jinek et al., 2012) . For the most commonly used Cas9 protein, that from Streptococcus pyogenes, the native PAM sequence is NGG, where N is any of the four DNA bases. Further studies have shown that the two-RNA tracrRNA and crRNA systems can be simplified by combining them into a single RNA molecule, the single-guide RNA (sgRNA), that maintains the ability to program Cas9's DNA cleavage activity (Jinek et al., 2012) . Unlike TALENs, Cas9 does not seem to be affected by the methylation state of the DNA .
The ability of Cas9 to mediate efficient RNA-programmed DNA cleavage has been demonstrated in many cell types and species, including cultured human cell lines (Cho et al., 2013; Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013b) , bacteria , yeast (DiCarlo et al., 2013) , zebrafish (Chang et al., 2013; Hwang et al., 2013a Hwang et al., , 2013b Jao et al., 2013; Xiao et al., 2013) , fruit fly (Bassett et al., 2013; Gratz et al., 2014; Yu et al., 2013) , mouse (Li et al., 2013a; Shen et al., 2013; Wang et al., 2013) , rat (Li et al., 2013a (Li et al., , 2013b , and monkey (Niu et al., 2014) . Engineered variants of Cas9, including mutants that lack the ability to cleave one or both DNA strands and fusions of Cas9 with other protein domains that regulate gene expression, have resulted in Cas9 nickases (Gasiunas et al., 2012; Jinek et al., 2012; Mali et al., 2013a; Ran et al., 2013) , transcriptional activators and repressors Cheng et al., 2013; Gilbert et al., 2013; Konermann et al., 2013; Maeder et al., 2013; Mali et al., 2013a; Perez-Pinera et al., 2013; Qi et al., 2013) , epigenetic modulators (Hilton et al., 2015; Kearns et al., 2015) , and sequence-programmable fluorophores for labeling DNA . Due to the ease with which sgRNAs can be transcribed or synthesized in test tubes, a microarray, or in cells, the use of hundreds or even tens of thousands of sgRNAs in a single experiment has been achieved, enabling large-scale screens that evaluate the effects of disrupting, activating, or repressing each of many different genes (Gilbert et al., 2014; Koike-Yusa et al., 2014; Konermann et al., 2015; Shalem et al., 2014; Wang et al., 2014; Zhou et al., 2014) .
Mechanism of DNA Recognition
The X-ray crystal structures of zinc-finger proteins (Fairall et al., 1993; Pabo, 1991, 1993) , TALE proteins (Deng et al., 2012; Mak et al., 2012) , and Cas9 Jinek et al., 2014; Nishimasu et al., 2014) have all been solved, revealing the molecular basis of DNA recognition. TALE proteins contain an N-terminal region (NTR), a central repeat domain (CRD), and a C-terminal region. Tandem repeats within the CRD wrap around the major groove of the DNA double helix, and a residue at position 13 specifically interacts with a single base along the DNA template (Deng et al., 2012; Mak et al., 2012) . Upon binding the target DNA, TALE proteins undergo a conformational change to a more compact form. This ability to switch between two different states, the ''search'' and ''recognition'' modes, allows the protein to search DNA quickly for the target sequence and bind DNA tightly once the target sequence is found (Cuculis et al., 2015) . Single-molecule studies by Schroeder, Zhao, and their respective coworkers have shown that TALEs diffuse rapidly in one direction along the DNA substrate, followed by a period of nearly stationary motion with extremely slow or no diffusion. TALEs were also shown to exhibit ''hopping'' events along the DNA in which they can quickly dissociate and re-associate with the DNA. Furthermore, by testing each TALE domain separately, the NTR region of the TALE was shown to exhibit fast one-dimensional diffusion along DNA templates suggesting that the NTR mediates initial binding and sliding along DNA. Extending the CRD to target longer stretches of DNA significantly slows the rate of protein diffusion (Cuculis et al., 2015) .
DNA curtain assays performed by Doudna, Greene, and their respective coworkers on Cas9:gRNA suggest that Cas9 does not find its target by facilitated diffusion . These experiments used lipid-tethered DNA molecules aligned at a diffusion barrier, which upon fluid flow, align to one another and form a curtain of DNA molecules (Fazio et al., 2008; Visnapuu and Greene, 2009 ). Cas9 programmed with a gRNA matching a site present in the DNA molecules was injected into the chamber, buffer flow was terminated, and reactions were visualized in real time. The data revealed long-lived binding events at the target site and transient binding events at other sites. Neither one-dimensional sliding nor hopping was observed; rather, all target recognition events appear to occur directly through three-dimensional collisions. The shorter-lived, non-specific binding events exhibited complex dissociation kinetics and indicated that Cas9 undergoes at least two and possibly more intermediates on the pathway toward cognate target recognition. Regions of the DNA with a higher abundance of the NGG PAM recognized by S. pyogenes Cas9 exhibited higher Cas9:gRNA occupancy, suggesting that Cas9 might bind specifically to PAM sites when searching for potential targets. Indeed, while Cas9 must transiently sample DNA lacking PAMs, these rapid binding events are not detectable in either single-molecule or bulk binding experiments . PAM recognition leads to a destabilization of the adjacent sequence followed by formation of the RNA-DNA heteroduplex. Only upon binding to a bona fide target locus do the nuclease domains in Cas9 activate.
Recent studies by Marszalek and coworkers also used atomic force microscopy (AFM) to shed light on the conformational changes that Cas9 undergoes upon binding to DNA (Josephs et al., 2015) . The results provide evidence of a ''conformational gating'' mechanism in which interactions between the gRNA and the 14th to 17th nucleotide region of the target DNA drives a Cas9 conformational change that leads to DNA cleavage. Both Cas9 and catalytically dead Cas9 (dCas9) were found to undergo progressive structural transitions as they bind to DNA. dCas9 molecules bound to sgRNA are predominantly smaller and egg-shaped but increase in both height and volume as they bind to target sequences. Catalytically active Cas9 undergoes a similar increase in size although is slightly smaller, possibly due to a final conformational change upon cleavage of the DNA (Josephs et al., 2015) . Using both structural data and size-exclusion chromatography, Doudna and coworkers also observed similar changes in the Cas9 conformation upon binding to the target DNA site (Jiang et al., 2015) .
Originally believed to be a multiple-turnover enzyme, recent studies suggest that at least in vitro Cas9 is a single-turnover enzyme. Doudna, Greene, and their respective coworkers conducted plasmid DNA cleavage assays with varying stoichiometries of Cas9:gRNA versus target DNA to determine whether stable product binding would prevent Cas9:gRNA from performing multiple-turnover cleavage . Varying the molar ratios of Cas9-RNA and target DNA and measuring the rate and yield of product formation revealed that the amount of cleaved DNA plateaued at a level proportional to the molar ratio of Cas9:gRNA to DNA. Elevating the temperature or providing an excess of free gRNA did not induce multiple turnovers. Additional experiments using a doubly tethered DNA curtain showed that Cas9:gRNA remains tightly bound to both ends of the cleaved DNA, thus limiting the enzyme to a single turnover . AFM imaging confirmed that most of the DNA molecules observed still contained a bound Cas9 and only 5% of DNA substrates were both cleaved and had separated from the Cas9 protein (Josephs et al., 2015) . In cells, where other DNA-binding cellular components are present, Cas9 in principle could be displaced from DNA and mediate additional DNA cleavage events although such an effect has thus far not been observed.
Off-Target Profiling of Genome-Editing Proteins
The ability of programmable DNA-binding proteins and nucleases to distinguish on-target from off-target DNA sequences is crucial for their application as research tools and potential human therapeutics. The specificity of ZFNs, TALENs, and Cas9 has been studied using a variety of methods both in vitro and in cells. Due to their concatameric nature, ZFNs and TALENs can theoretically be expanded to extend DNA specificity. However, expanding the number of zinc-finger or TALE repeats also increases the likelihood that a partial match with an offtarget sequence is sufficient to support DNA binding.
In vitro and cell-culture studies on TALEN specificity have not only substantiated off-target activity but also elucidated design principles for improving specificity. Testing three distinct sequences, CCR5A, CCR5B, and ATM, Liu and coworkers profiled the DNA cleavage specificity of 30 unique heterodimeric TALEN pairs with different C-terminal, N-terminal, and FokI domain variants using an in vitro selection method that evaluates the ability of each TALEN to cleave DNA at each of 10 12 different potential substrate sequences that are related to the on-target sequence (Guilinger et al., 2014a) . The results of the in vitro specificity profile correctly predicted off-target DNA substrates in the human genome for the CCR5A-and ATM-targeting TALENs that were detectably modified by these TALENs in human cells. More recently, a modified high-throughput, genome-wide translocation sequencing (HTGTS) method was used by Alt and coworkers to detect DNA double-stranded breaks induced by TALENs in a genome-wide fashion (Frock et al., 2015) . Two TALENs were studied that cleave C-MYC or ATM. A large number of off-target sites were detected for both of these targets: 522 offtarget sites for ATM and 384 off-target sites for C-MYC. Many highly enriched TALEN off-targets were pseudo-palindromic sequences that correspond to variants of the recognition site of a single TALEN monomer, suggesting that the binding energy of these single monomers were enough to bind and activate DNA cutting (Frock et al., 2015) . Other large-scale studies such as one conducted by Bulyk and coworkers quantitatively assayed the DNA-binding specificities of 21 representative TALEs to 5,000-20,000 unique DNA sequences per protein using custom-designed protein-binding microarrays (Rogers et al., 2015) . Using the data from the study, the Specificity Inference for TAL-Effector Design tool was created that models the intrinsic specificity of each RVD and considers a variety of repeat context features, including the number of repeats in the protein, each repeat's position within the repeat array, and the immediately neighboring N-and C-terminal repeat types. Further analysis by Baldwin, Segal, and their respective coworkers on TALE specificity also determined that RVD choice can affect affinity to the DNA target by four orders of magnitude (Meckler et al., 2013) . In addition, base mismatches at the 5 0 end of the target site had more disruptive effects on affinity than those at the 3 0 end. Researchers have developed and applied similar methods for analyzing the DNA specificity of Cas9. Initial studies from several groups showed that some single-base mutations could be tolerated, especially in nucleotides distal from the PAM sequence Jiang et al., 2013; Jinek et al., 2012) . Early results suggested that a ''seed sequence,'' the 8-10 nucleotides immediately adjacent to the PAM, was the primary determinant of Cas9 DNA recognition specificity (Jinek et al., 2012; Semenova et al., 2011; Wiedenheft et al., 2011) . Later studies have shown, however, that while more sensitive to mutations than at distal positions, off-target substrates can still contain mutations in the seed sequence Hsu et al., 2013; Mali et al., 2013a; Pattanayak et al., 2013) . Further studies by Liu and coworkers used libraries that enabled the broad discovery of offtarget sequences both in vitro and in human cells and concluded that off-target substrates cleaved by Cas9 could contain even five mismatches (Pattanayak et al., 2013) . These methods use focused deep sequencing to identify indel mutations at potential off-target sites but also likely missed other off-target substrates as they assume that off-target sequences are closely related to the on-target sequence. The ability of Cas9 to bind and cleave at DNA sites that contain insertions (DNA bulge) or deletions (RNA bulge) relative to the gRNA also increase the difficulty of predicting off-target sites Lin et al., 2014b; Ran et al., 2015) . Several groups have used ChIP-seq to find a large number of potential off-target binding sites of dCas9, but very few of these sites appear to represent off-target sites of cleavage by active Cas9 nuclease (Duan et al., 2014; Kuscu et al., 2014; O'Geen et al., 2015; Wu et al., 2014) . As cells are cross-linked post-transfection, false positives could arise due to transient interactions between Cas9 and genomic DNA (O'Geen et al., 2015) . Whole-genome sequencing has been used to identify off-target alterations in edited single-cell clones (Smith et al., 2014; Veres et al., 2014; Yang et al., 2014) , but such a method is impractical to perform at the depth necessary to detect low-frequency genome modification events needed to detect many off-target substrates that are only weakly modified.
For example, detecting less than 1% modification would require sequencing thousands of whole genomes using such an approach.
More recently, researchers have developed methods to identify genomic double-stranded breaks in human cells in an unbiased manner that does not presume that off-target substrates are similar to on-target sequences. These methods were used to profile TALENs, Cas9, and the Cas9 D10A paired nickase as well as modified gRNAs. Using blunt-double-stranded oligodeoxynucleotides (dsODNs) as tags that are inserted into the genome upon double-stranded breaks and repair through an end-joining process consistent with NHEJ, Joung and coworkers used a method called genome-wide unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) to characterize off-target sequences of 13 Cas9:sgRNA complexes in two human cell lines, U2OS and HEK293 . Consistent with previous results, as many as six mismatches were found in the protospacer sequence for off-target sites. Non-canonical PAMs such as NAG, NGA, NAA, NGT, NGC, and NCG, were also all found among sites that were cleaved by Cas9. Greater numbers of mismatches decreased the likelihood of being cleaved, mismatches near the 5 0 end of the target site were more tolerated than at the 3 0 end, although mismatches 1-4 bp away from the PAM were somewhat better tolerated than those 5-8 bp away, and wobble mismatches were found to be more highly tolerated than non-wobble mismatches. Interestingly, the number of off-target sites identified for each Cas9:sgRNA varied greatly from zero to >150 . Similarly, Alt and coworkers used the HTGTS method to find variable off-target modification frequencies for four RAG1-targeting Cas9:sgRNA complexes, with two of the four showing no detectable offtarget activity (Frock et al., 2015) .
A separate method, Digenome-seq, developed by Kim and coworkers also observed that off-target activity was highly variable depending on the targeted site (Kim et al., 2015) . In Digenome-seq, human genomic DNA is digested using Cas9 nuclease in vitro. The resulting DNA is then subjected to whole-genome sequencing and Cas9 cleavage sites are identified by looking for sequence reads that are vertically aligned that represent DNA fragments with identical 5 0 ends. Using this method, a total of 80 potential off-target sites were identified for one Cas9:sgRNA that targeted VEGF. All 80 sites and an additional 28 sites representing off-target sites that differ from the on-target sites by three or fewer nucleotides were further investigated by targeted deep sequencing. Four previously identified off-target sites were validated and four new off-target sites captured by Digenome-seq also showed off-target cleavage. These off-target sites contained up to six nucleotide mismatches, highlighting the large number of mismatches between the guide RNA and DNA substrate that in some cases can be tolerated by Cas9 (Kim et al., 2015) .
Zhang and coworkers also interrogated the genome-wide offtarget cutting activity of both Streptococcus pyogenes and Staphylococcus aureus Cas9 (Ran et al., 2015) . In the BLESS (direct in situ breaks labeling, enrichment on streptavidin, and next-generation sequencing) method (Crosetto et al., 2013) , cells were transfected with either S. pyogenes Cas9 or S. aureus Cas9, and fixed. Free genomic DNA ends were captured using biotinylated adaptors and analyzed by deep sequencing. A sequencing pipeline filters out the background double-stranded break (DSB) clusters and assigns DSB scores by comparing the count of DSBs in the experimental and negative control samples. Top-ranked off-target sites identified by BLESS were verified using targeted deep sequencing to detect indel formation. Only sites that contained a PAM and homology to the guide sequence exhibited indels. Consistent with similar genome-wide off-target studies, BLESS revealed additional off-target sites not previously predicted by simple sequence similarity to the target or by ChIP (Ran et al., 2015) . Additional off-target sites contained not only Watson-Crick base-pairing mismatches to the guide but also insertion and deletion mismatches between the gRNA and the target DNA, consistent with other reports Lin et al., 2014b; Ran et al., 2015) .
Protein Engineering and Evolution to Improve GenomeEditing Specificity
In light of the imperfect specificity of wild-type or canonical programmable nucleases, researchers have sought to improve specificity using several strategies including protein engineering and evolution. Soon after the discovery of the catalytic domains of Cas9, two mutations in the conserved HNH and RuvC nuclease domains, D10A and H840A, respectively, were used to abolish the nuclease activity of Cas9 to form dCas9 (Jinek et al., 2012) . Since each domain mediates the cleavage of one DNA strand, either mutation by itself creates a Cas9 nickase that only cleaves a single strand of DNA. Church and coworkers and Zhang and coworkers independently demonstrated the use of pairs of the D10A Cas9 nickase (Cas9n) to induce double-stranded genomic breaks by using two gRNAs to target the Cas9n to nearby sites offset up to 100 bp ( Figure 2A ) (Mali et al., 2013a; Ran et al., 2013) . The requirement of two independent nicking events relatively close to each other on opposite strands in order to cause a DSB increases the specificity of paired Cas9 nickases relative to wild-type Cas9. Deep sequencing of known off-target sites in cells either transfected with wild-type Cas9 or Cas9n showed 50-to 1,500-fold greater specificity of the nickase compared with that of wild-type Cas9 .
Fusion of dCas9 to FokI (creating fCas9), similar to the strategy used in ZFNs and TALENs, also increases DNA cleavage specificity relative to wild-type Cas9 as shown independently by Liu and coworkers, Joung and coworkers, and Mahfouz and coworkers (Aouida et al., 2015; Guilinger et al., 2014b; Tsai et al., 2014) . By fusing FokI to the N terminus of dCas9, fCas9 requires the assembly of two FokI monomers at the target site to induce double-stranded DNA cleavage ( Figure 2B ). The spacing requirements of fCas9 are more stringent than what is required for Cas9n, with optimal activity achieved when the two target sites are either 15 or 25 base pairs apart (Guilinger et al., 2014b) . As a result, the specificity of fCas9 was shown to be higher than that of paired nickases at loci with highly similar off-target sites (Aouida et al., 2015; Guilinger et al., 2014b; Tsai et al., 2014) .
The engineering of monomeric forms of programmable nucleases has also been used to substantially improve their DNA specificity. Following the use of the in vitro specificity profiling method described above on ZFNs, TALENs, and Cas9, Liu and coworkers hypothesized that excess DNA-binding energy erodes the specificity of genome-editing agents, and speculated that reducing the strength of non-specific DNA-binding interactions could improve the specificity of these nucleases by decreasing off-target DNA binding while still allowing the nuclease to bind on-target sequences (Guilinger et al., 2014a; Pattanayak et al., 2011 Pattanayak et al., , 2013 . Indeed, the researchers found that changing cationic Lys or Arg residues that do not make base-specific contacts with DNA to neutral Gln residues could increase the DNA cleavage specificity of TALENs in cells by 10-to 100-fold, without necessarily decreasing activity for on-target sequences (Guilinger et al., 2014a) . Given that wildtype Cas9 with full-length sgRNA can cleave a wide variety of sequences and has likely evolved to tolerate some degree of mutation among natively targeted viral DNA sequences, it is likely that the Cas9:sgRNA-DNA binding interaction is also stronger than is necessary for nuclease function, and that reducing this excess DNA-binding energy can decrease off-target activity while maintaining on-target activity in a manner similar to the improved specificity of the engineered TALENs. Indeed, Joung and coworkers demonstrated improvements in Cas9 specificity with truncated sgRNAs (see below) (Fu et al., 2014) , and Zhang and coworkers recently identified specificity-enhancing mutations in Cas9 that neutralize positively charged residues in the nontarget strand groove (Slaymaker et al., 2015) . By generating S. pyogenes Cas9 mutants consisting of individual alanine substitutions at 32 positively charged residues, the authors were able to identify mutations that could lead to higher specificity without decreasing on-target cleavage efficiency. Top single amino acid mutants were combined and tested to identify three Cas9 mutants with both high efficiency of cutting at the on-target site and improved specificity. Similarly, Joung and coworkers developed a S. pyogenes Cas9 variant with improved DNA specificity by testing combinations of up to four mutations in which cationic residues that contact the phosphate backbone of the target DNA strand were changed to neutral alanine residues (Kleinstiver et al., 2016) . Some variants showed comparable activity to wild-type Cas9 for most targets tested but virtually no off-target DNA cleavage activity detected by genome-wide and targeted sequencing methods.
Laboratory evolution efforts on TALENs and Cas9 have also revealed mutations within each protein that can alter or enhance DNA specificity. Through a positive selection on an on-target site and negative selection against cleaving a known off-target site, Liu and coworkers used phage-assisted continuous evolution to generate more specific TALE proteins that target the human ATM locus (Hubbard et al., 2015) . Interestingly, specificity profiling against 10 12 other off-target sites that were not used in the negative selection revealed that the evolved TALENs showed broad specificity improvements across virtually all recognized DNA positions, indicating that the specificity of the TALENs was broadly improved, rather than only improved against the selected off-target sequence (Hubbard et al., 2015) . While evolving S. pyogenes Cas9 variants that accept non-canonical PAM sequences, Joung and coworkers discovered a D1135E mutation that improves discrimination between NGG and NGA PAM sequences (Kleinstiver et al., 2015) . This single mutation led to increased specificity at 19 of the 22 off-target sites tested using deep sequencing of known off-target sites. GUIDE-seq using three different sgRNAs also suggested that these evolved Cas9 variants show general improvements in genome-wide specificity relative to wild-type Cas9 (Kleinstiver et al., 2015) .
Guide RNA Modifications to Improve Genome-Editing Specificity Engineering guide RNAs can also improve Cas9 specificity by increasing the requirements for interacting with the DNA target. Some of these modifications lead to less activity overall, highlighting a tradeoff between activity and specificity. For example, early sgRNA architectures varied the length of the sgRNA backbone, extending the Cas9-binding sequence by ten bases to form a more active variant Jinek et al., 2012; Mali et al., 2013b) . Comparing the shorter, less-active variant to the longer, more active variant commonly used, on-target modification can be substantially lower with the shorter sgRNA, but off-target modification is also minimized and can drop below the limit of detection at some sites in which the more active sgRNA exhibits off-target activity . Using sgRNA variants with shorter regions of target complementarity can also improve specificity, in most cases without sacrificing on-target genome-editing efficiencies. Hypothesizing that off-target effects of Cas9 can be minimized by decreasing the length of the sgRNA-DNA interface and that 5 0 -end sgRNA:DNA interactions might compensate for mismatches at other positions along the interface, Joung and coworkers tested sgRNAs with progressively shorter regions of complementarity for a target site in an EGFP reporter (Fu et al., 2014) . The researchers found that truncated sgRNAs (trugRNAs) with 17 or 18 nucleotides of target complementarity, instead of the canonical 20 nucleotides, functioned as efficiently as canonical sgRNAs for different EGFP targets ( Figure 2C ). On sites from three human genes, VEGFA, EMX1, and CLTA, five of the seven tested trugRNAs induced Cas9-mediated indel formations at comparable rates as full-length sgRNAs. Comparing the specificity of these trugRNAs versus full-length sgRNAs, Cas9 with trugRNAs generally appear to induce either very low or undetectable levels of mutations at potential off-target sites that differ by one or two mismatches compared with full-length sgRNAs that can induce cutting at off-target sites bearing up to four or five mismatches. trugRNAs were also tested with paired Cas9 nickases at four off-target sites of the VEGF gene, revealing that the combination of the two approaches led to undetectable off-target mutation rates, whereas either approach by itself induced detectable off-target mutations (Fu et al., 2014) .
These specificity improvements likely arise by reducing excess DNA-binding energy, similar to the basis of improved specificity among evolved TALEN and Cas9 proteins described above. Cas9 paired with trugRNAs can be more specific nucleases since the reduced excess DNA-binding energy creates a situation in which nucleotide mismatches in an off-target sequence erodes the strength of the Cas9:trugRNA-DNA interaction below the necessary threshold for productive DNA binding or cleavage.
Further studies by Church, Weiss, and their respective coworkers using truncated guide RNAs also showed that even shorter guides, while not competent to mediate DNA cleavage, can still be used with dCas9 for DNA binding (Kiani et al., 2015) . This finding establishes that Cas9 DNA binding and cleavage can be decoupled, and that the cleavage does not necessarily follow DNA binding even when the nuclease domains within Cas9 are present. By using Cas9, Cas9-VPR (consisting of the tripartite transcriptional activator VP64-p65-Rta), and dCas9-VPR with truncated gRNAs with 20-, 16-, or 14-nt complementarity, Weiss, Church, and coworkers tested the ability of each truncated gRNA to either bind or cleave DNA. Cas9-VPR was able to induce target chromosomal gene expression with either 16-nt or 14-nt gRNA, but not 20-nt gRNA, as the 20-nt gRNA led to DNA cleavage. Cas9-VPR with 14-nt gRNAs was able to activate expression of all targets tested to at least 40% of the expression level of Cas9-VPR with full-length gRNAs. No mutagenesis was observed using the 14-nt gRNA, while indels were observed in some cases using the 16-nt gRNAs, and in all cases using the 20-nt gRNAs (Kiani et al., 2015) . In addition to establishing the ability to use a single Cas9 construct fused to a transcriptional activation domain for gene activation, repression, and cleavage, the use of shortened gRNAs also illuminate the relationship between gRNA-DNA interaction and Cas9 effector function.
Interestingly, the addition of two guanine nucleotides to the 5 0 end of gRNA can also increase Cas9:sgRNA specificity ( Figure 2C ) Kim et al., 2015) . Kim and coworkers found that these ''ggX 20 '' gRNAs, where the lowercase g represents a mismatched guanine, increase specificity up to 660-fold compared with conventional gRNAs on the basis of on-target to off-target indel frequencies (Kim et al., 2015) . The extra, mismatched guanines did not lead to substantially lower activity when compared with a regular 20-nt gRNA with either a mismatched or matched guanine at the 20th position in one cell line tested, but did lead to lower activity in a second cell line tested. These observations are consistent with a model in which the extra guanines weaken RNA:DNA binding energetics, which may or may not affect on-target activity depending on the degree of excess binding energy between the unmodified gRNA and DNA (Kim et al., 2015) .
Controlling Genome-Editing Agents
For virtually all desired genome-editing applications, only a single on-target sequence is present in the genome, typically in one or two copies per cell. As a result, once the on-target site has been successfully modified, the presence of an active genome-editing agent is undesirable since it can only mediate off-target DNA modification, or even mediate further undesired modification of the target locus. Therefore, excess genomeediting protein activity, either in time or in dosage, erodes genome-editing specificity. The inverse relationship between activity and specificity was described in early reports of decreased genome-editing specificity upon treatment with higher concentrations of Cas9 Hsu et al., 2013; Pattanayak et al., 2013) . Unlike traditional therapeutics that require exposure to long, sustained activity, the exposure of cells to genome-editing activity should be minimized such that cells receive only enough exposure to effect desired levels of on-target modification in the genome. This goal can be achieved by restricting the production or activation of genome-editing proteins through molecular engineering strategies, or by transiently delivering genome-editing agents in mRNA or protein form, rather than delivering DNA constructs that produce genome-editing proteins at high levels for long periods of time.
Small-Molecule Control of Cas9 Activity
Limiting the activity of a genome-editing protein to a short temporal window using a small molecule can improve specificity by reducing the opportunity for off-target modification events. At the simplest level, small-molecule control of Cas9 activity can be achieved with a small-molecule-induced promoter that regulates Cas9 or gRNA expression (Aubrey et al., 2015; Dow et al., 2015; Gonzalez et al., 2014; Wang et al., 2014) . Huangfu and coworkers created a panel of human pluripotent stem cells with Cas9 expression under the control of the tetracycline response element, enabling stage-specific gene knockout during differentiation following doxycycline treatment (Gonzalez et al., 2014) . Herold and coworkers developed a dual lentiviral system consisting of constitutively expressed Cas9 and a gRNA cassette regulated by the tetracycline repressor, allowing doxycycline-induced deletion of genes that are essential for cell survival (Aubrey et al., 2015) . Lowe and coworkers developed a conditional transgenic approach for inducible genome editing in adult mice, enabling the easy generation of in vivo conditional, knockout models (Dow et al., 2015) . Collectively, these studies establish temporally controlled genome editing by small-molecule induction of Cas9 or gRNA expression. Post-translational strategies that directly control the activity of Cas9 protein, rather than the induction of the relative slow processes of mammalian cell transcription and translation, enable higher temporal resolution. Small-molecule controlled zinc-finger proteins (Beerli et al., 2000; Pollock et al., 2002; Xu et al., 2001 ) and TALE transcriptional activators (Mercer et al., 2014) have been generated using steroid-induced conformational modulation systems or chemically induced dimerization systems. Otonkoski and coworkers developed a small-molecule-inducible dCas9-based transcriptional activator (Balboa et al., 2015) that uses the N-terminal fusion of a dihydrofolate reductase destabilizing domain (DHFR DD) (Iwamoto et al., 2010) , which leads to the rapid degradation of the entire protein in the absence of the small molecule trimethoprim. In the presence of trimethoprim, the DHFR DD is stabilized, resulting in the persistence of active dCas9 fused to repeats of the VP16 activator domain. The researchers used this conditionally stabilized dCas9 activator to control gene expression in human cell reprogramming and differentiation (Balboa et al., 2015) . Porteus and coworkers used a similar strategy involving N-terminally fused destabilizing domains to control genome editing with ZFNs, and showed that this strategy was effective in reducing cytotoxicity associated with off-target cleavage (Pruett-Miller et al., 2009 ).
Liu and coworkers achieved small-molecule post-translational activation of Cas9 activity using a ligand-dependent intein (Davis et al., 2015) . Inteins that undergo protein splicing in the presence of the cell-permeable small molecule 4-hydroxytamoxifen (4-HT) were previously developed by protein engineering and directed evolution (Buskirk et al., 2004; Peck et al., 2011) . The researchers studied 15 insertion sites in Cas9 for this ligand-dependent intein and identified eight locations for which the intein disrupts Cas9 activity but for which activity is restored following 4-HT treatment ( Figure 3A) . Two of the best-performing variants representing intein insertions at Ser 219 and Cys 574 were evaluated for their genome-editing specificity compared with that of wild-type Cas9. At 11 previously described off-target sites of gRNAs targeting EMX, VEGF, and CLTA, both intein-Cas9s exhibited substantially improved specificity relative to wild-type Cas9, with an average of six-fold higher on-target/off-target genome modification ratios in human cells compared with that of wildtype Cas9 (Davis et al., 2015) .
Zhang and coworkers achieved small-molecule-triggered post-translational activation of Cas9 using split Cas9 halves in which the N-terminal half was fused to FKBP rapamycin binding (FRB) domain and the C-terminal half was fused to FK506 binding protein 12 (FKBP) (Zetsche et al., 2015b) . The addition of rapamcyin mediates dimerization of the split Cas9 halves, restoring Cas9 activity. The researchers noted background activity in the absence of rapamycin due to self-assembly of the fragments in cells, and minimized this background assembling by replacing the nuclear localization sequence (NLS) on the N-terminal fragment with a nuclear export sequence (NES) to spatially separate the two fragments. When Cas9(N)-FRB-NES dimerizes with Cas9(C)-FKBP-2xNLS in the presence of rapamycin, the entire Cas9 protein is trafficked to the nucleus ( Figure 3B ). Cells transduced with lentivirus carrying the split Cas9 showed on-target indel frequency of 43% after 12 days of rapamycin treatment compared with 95% indel frequency with wild-type Cas9. Importantly, with the split Cas9, no significant modification at the off-target sites was detected, whereas indel frequency at the same sites with wild-type Cas9 ranged from <1% to 38% (Zetsche et al., 2015b) . Sato and coworkers similarly split Cas9 at 18 different sites, with FRB fused to the N-terminal fragment and FKBP fused to the C-terminal fragment (Nihongaki et al., 2015a) . They found that splitting Cas9 between residues 713 and 714 yielded the best ligand dependence and used this work to inform their development of a photoactivatable Cas9 described below.
These studies collectively demonstrate that the use of smallmolecule control of genome-editing activity can improve genome modification specificity while maintaining efficient on- target activity. Bursts of controlled activity from genome-editing proteins can lead to substantial levels of on-target cutting but greatly reduced off-target effects.
Optical Control of Cas9 Activity
Light offers an alternative method of spatiotemporal control over protein activity that is non-invasive. Light-inducible gene regulators have been generated by fusing one half of a light-triggered heterodimerizing protein pair to a programmable DNA-binding domain and the other half to an effector domain. To enable optical control over genome editing, Sato and coworkers developed a photoactivatable Cas9 (paCas9) by splitting Cas9 into two fragments, each fused to a photoinducible dimerization domain (Nihongaki et al., 2015a) . The researchers replaced FKBP/FRB in the split Cas9 described above with paired photoswitchable proteins (pMag and nMag) from the Magnet system (Kawano et al., 2015) yielding paCas9 ( Figure 4A ). While paCas9 has lower activity than that of wildtype Cas9, it can induce targeted genome editing by NHEJ and HDR in a light-dependent manner. Photoactivatable and reversible inhibition of gene expression (CRISPRi) can also be achieved using photoactivatable dCas9 (padCas9), which contains the D10A and H840A mutations and cannot cleave DNA (Nihongaki et al., 2015a) .
Building on similar work with zinc fingers (Polstein and Gersbach, 2012 ) and TALE proteins , Gersbach and Polstein, and Sato and coworkers independently developed two Cas9-based light-inducible gene activation systems (Nihongaki et al., 2015b; Polstein and Gersbach, 2015) . Both of these systems use the Arabidopsis thaliana proteins cryptochrome 2 (CRY2) and cryptochrome-interacting basichelix-loop-helix (CIB1) that dimerize upon exposure to blue light (Kennedy et al., 2010; Liu et al., 2008) . The light-activated CRISPR-Cas9 effector (LACE) system developed by Gersbach and Polstein fuses CIBN, a truncated version of CIB1, to the N and C termini of dCas9, and CRY2 to the transcriptional activator VP64 ( Figure 4B ) (Polstein and Gersbach, 2015) . Using LACE, gene activation can be controlled both spatially and temporally. Sato and coworkers developed a similar Cas9-based photoactivatable transcription system in which dCas9 is fused to trCIB1, a C-terminal truncated CIB1, and the transcriptional activator p65 is fused to CRY2PHR, the photolyase homology region of CRY2 (Nihongaki et al., 2015b) . While this strategy of light-induced effector localization has only been demonstrated with transcriptional activators thus far, in principle it should be applicable to other effectors such as epigenome-modifying enzymes, as demonstrated by the light-inducible transcriptional effectors system developed by Zhang and coworkers using TALE proteins .
Deiters and coworkers achieved optical control of genome editing using site-specific non-natural amino acid incorporation to replace an essential lysine residue with a photocaged lysine (PCK) (Hemphill et al., 2015) . UV exposure uncages the lysine, restoring Cas9 activity. An initial screen of several lysine residues identified two sites, K163 and K866, which when replaced with PCK enabled optical uncaging of Cas9. The K866 site, which undergoes a significant conformational change upon gRNA binding, was chosen as the best site due to minimal background activity and wild-type-like activity following UV irradiation (Hemphill et al., 2015) . In order to genetically encode the PCK unnatural amino acid, an engineered pyrrolysyl tRNA/tRNA synthetase pair must be used, limiting the in vivo application of this technique; however, ribonucleoprotein delivery of the K866PCK Cas9 mutant could potentially overcome this limitation (see below).
While these optically controlled gene-editing strategies have not yet been explicitly tested for their ability to improve genome-editing specificity following limited treatment with light, based on the above results from small-molecule inducible Cas9, similar improvements in specificity are likely to result from carefully controlling the temporal window of Cas9 activity. While the in vivo use of optically controlled genome editing and regulation is limited by the depth to which light can penetrate tissue, in cultured cells these systems offer high-resolution spatial and temporal control.
Delivery of Genome-Editing Proteins
Unlike traditional enzyme therapy or gene therapy approaches, genome editing requires only the transient exposure of cells to active protein. Indeed, long, sustained transgene expression methods that are typically used for gene therapy can be detrimental in genome-editing applications for which off-target effects are a major concern. Expression of genome-editing proteins in vivo can be achieved through DNA delivery using viral vectors or plasmid DNA. More transient expression can be achieved by delivery of mRNA encoding genome-editing proteins. Electroporation and lipid-based transfection can mediate the non-viral delivery of nucleic acids and purified protein.
Compared with mRNA and, especially, DNA delivery, protein delivery offers the highest degree of control over dosage and temporal exposure of cells to genome-editing agents. As a result, protein delivery in principle offers unique benefits for genomeediting applications over more commonly used DNA or RNA transfection or viral infection approaches.
Several recent studies have established the delivery of purified genome-editing proteins. The short intracellular half-life of most proteins in cells can limit off-target effects while still allowing levels of modification at on-target sites that are comparable with those of DNA-or mRNA-delivery approaches. Since Cas9-mediated genome editing requires both the Cas9 protein and the gRNA, delivery methods must be able to deliver both either separately or together as a ribonucleoprotein complex. In special cases, delivery of only one component may suffice if the other is being constitutively expressed (Platt et al., 2014) .
Electroporation can be used to deliver purified Cas9:sgRNA ribonucleoproteins (RNPs) into cells Lin et al., 2014a) . Kim and coworkers showed that in human leukemia K562 cells, RNP electroporation resulted in genome modification efficiencies of 16%-72% . In cell lines that are refractory to DNA transfection such as BJ fibroblasts and pluripotent stem cells, protein delivery via electroporation was at least two-fold more efficient than plasmid transfection. RNP delivery by electroporation led to genomic DNA modification almost immediately after delivery, with indel frequency plateauing after 24 hr. Western blotting showed that the Cas9 protein was almost completely degraded 24 hr after delivery. Plasmid transfection led to comparable levels of genome modification but required 3 days and resulted in the expression of Cas9 for several days thereafter. These differences led to a 9.5-fold and 13-fold higher on-target to off-target indel frequency for two different AAVS1-S3 sites for protein delivery compared with DNA transfection. Importantly, the greater specificity of genome editing from protein delivery did not sacrifice on-target activity .
Direct protein delivery by molecular delivery platforms is potentially more relevant to in vivo applications than electroporation but has proven more challenging. ZFNs were found, fortuitously, to have intrinsic cell-penetrating capabilities (Gaj et al., 2012) , and Barbas and coworkers demonstrated that direct delivery of ZFNs resulted in reduced off-target effects compared with plasmid transfection. To enable direct delivery of TALENs, cellpenetrating peptides (CPPs) were used to enhance the delivery of these proteins Ru et al., 2013) . CPPs have also been applied to Cas9 by Kim and coworkers (Ramakrishna et al., 2014) . The researchers were able to effectively modify human cells by delivering Cas9 conjugated via a thioether bond to a CPP containing four glycines, nine arginines, and four leucines, along with an sgRNA complexed with a similar CPP containing one cysteine, three glycines, nine arginines, four leucines, and one cysteine. Genetically fusing the CPP to Cas9 resulted in poor purified protein yields, so Cas9 was genetically modified to contain a C-terminal cysteine residue to enable conjugation with a maleimide-linked CPP. Using this method, the researchers observed 2.2-to 4.1-fold higher specificity compared with that following plasmid transfection (Ramakrishna et al., 2014) .
Liu and coworkers recently discovered that common cationic lipid nucleic acid transfection reagents can potently deliver proteins that are covalently or non-covalently bound to highly anionic macromolecules . This method of delivery provides an alternative to traditional nucleic acid and viral delivery and can mediate the potent delivery of proteins both in cell culture and in vivo. While few proteins natively possess the highly anionic character of nucleic acids, fusion of proteins with an engineered, supernegatively charged GFP enables efficient complexation and delivery of proteins into cultured mammalian cells by cationic lipids (Figure 5 ). To test the time course of delivered activity, TALE-VP64-(-30)GFP fusions were used to activate the expression of NTF3 in HEK293T cells. Following protein delivery, NTF3 mRNA levels peak 4 hr after treatment and fall to <25% of peak levels over the next 44 hr. In contrast, DNA plasmid transfection required 24 hr to induce NTF3 expression, which was sustained at high levels for >48 hr . These results demonstrated that protein delivery results in rapid-on, rapid-off time courses of activity that are more suited for most genome-editing applications than common DNA delivery approaches for the reasons articulated above. The researchers also found that Cas9, when complexed with naturally polyanionic sgRNA, can be delivered in unmodified form using this strategy simply by combining the Cas9:sgRNA complex with commercially available cationic lipids commonly used to deliver DNA or RNA into mammalian cells . Delivery of Cas9:sgRNA complexes using this method can lead to up to 80% target gene disruption, as well as 10% HDRmediated gene correction, in cultured human cells from a single treatment. Efficient in vivo genome modification was also shown in the inner ear of live mice through injection of Cas9:sgRNA:lipid complexes .
Because the direct delivery of genomeediting proteins results in more transient exposure of the cell to the genome-editing agent compared with DNA delivery, the specificity of protein delivery-based genome editing is expected to increase compared with that of plasmid transfection or viral infection. Indeed, the off-target modification frequency in HEK293T cells was substantially lower for protein delivery compared with plasmid delivery at all 11 off-target sites tested, even when the on-target modification efficiency was comparable at 10% ± 2%. The ratio of on-target to off-target modification, however, was up to 19-fold higher for protein delivery. The substantially higher specificity of protein delivery-based genome editing compared with DNA delivery was consistently observed across a range of modification conditions that resulted in on-target modification efficiencies from 1% to 40% .
Additional studies by Potter and coworkers using both cationic lipids and electroporation to deliver purified Cas9 protein also compared the off-target cleavage activity of Cas9 delivered in DNA, mRNA, or RNP forms (Liang et al., 2015) . For one site within VEGFA, delivery of mRNA and Cas9 RNP into cells were 2-fold and 2.5-fold more specific, respectively, for on-target versus off-target modification compared with plasmid DNA delivery. At a second VEGFA site, mRNA and protein delivery were 1.6-fold and 28-fold more specific, respectively, than plasmid DNA delivery (Liang et al., 2015) . Thus, Cas9 protein delivery was again shown to result in higher genome modification specificity than DNA transfection, likely due to its more transient nature in cells, and may also result in higher specificity than delivery of the corresponding mRNA. Interestingly, increasing the amount of Cas9 protein delivered led to higher on-target activity levels but a smaller rise in off-target activity levels, consistent with a model in which much of the off-target genome modification events arise from Cas9 activity over long time windows.
The efficient intracellular delivery of native proteins can also be accomplished using induced transduction by osmocytosis and propanebetaine (iTOP) (D'Astolfo et al., 2015) . Geijsen and coworkers demonstrated that a number of different proteins and small RNAs, including Cas9 and sgRNAs, can be delivered to a wide variety of primary cells using this method. iTOP relies on NaCl-mediated hyperosmolality and propanebetaine to trigger macropinocytotic uptake and subsequent intracellular release. Using iTOP-CRISPR/Cas9, the endogenous gene DPH7, which is essential for diphtheria toxin lethality, could be knocked out with high efficiency in primary human stem cells (D'Astolfo et al., 2015) .
Cas9 and sgRNA can also be delivered using self-assembled DNA nanoparticles (Sun et al., 2015) . Gu, Beisel, and their respective coworkers used DNA nanoparticles synthesized by rolling circle amplification to encapsulate Cas9 and an sgRNA. The resulting DNA ''nanoclews'' contain palindromic sequences that drive the self-assembly of the nanoparticles and by including sequences with partial complementarity to the sgRNA, Cas9-bound sgRNA was effectively loaded into these structures. The Cas9-sgRNA loaded nanoparticles were subsequently coated with the cationic polymer polyethylenimine to facilitate endosomal escape. Using this method of delivery, targeted genome editing of an EGFP locus was accomplished in human U2OS cells with 28% efficiency (Sun et al., 2015) .
Conclusions
The discovery and development of ZFNs, TALENs, and Cas9 have provided researchers with an unprecedented ability to manipulate the genomes of a wide range of organisms in a sequence-programmable manner. Realizing the full potential of these powerful tools for research or therapeutic applications, however, requires tailoring their characteristics to improve their specificity, control their activity, and facilitate their delivery into target cells. Chemical biology approaches to regulating protein activity, specificity, and localization are therefore ideally suited to advance programmable nucleases toward augmented research capabilities and increased therapeutic relevance.
Chief among the shortcomings of canonical genome-editing proteins are their imperfect DNA modification specificities. Unbiased, broad DNA specificity profiling of programmable nucleases both in the test tube and in cells has led to a deeper understanding of the factors that contribute to target-specific versus non-specific DNA binding. Reducing excess DNA-binding energy through disrupting non-specific interactions (typically electrostatic contacts between cationic protein side chains and the anionic nucleic acid phosphate backbone) has already led to engineered genome-editing agents with improved DNA specificity. Laboratory evolution approaches have also identified variants of these proteins with wild-type-like activity for on-target sequences but reduced off-target activity, possible through similar mutations that create imperfections in the protein:DNA binding interface. In the case of Cas9, guide RNA modifications that increase the energetic requirements for productive Cas9: sgRNA:DNA complex formation have also proven effective at enhancing specificity.
A second approach to substantially improving specificity exploits the non-steady-state nature of genome editing. Because only one or two copies of the target locus typically exist in a cell, in contrast to a much greater number of off-target substrates, limiting the activity or lifetime of genome-editing proteins such that they do not linger in active form in the cell after mediating target locus modification has also greatly improved genome-editing specificity. To achieve this control, researchers have engineered variants of these proteins that are only active in the presence of certain cell-permeable small molecules or light of a specific wavelength. In most cases, the specificity of these controllable genome-editing proteins improves compared with that of the uncontrolled, canonical forms, without substantially sacrificing on-target modification efficiency.
Finally, the method of delivering these genome-editing proteins into cells has also been shown to influence their efficiency and specificity. In contrast to traditional gene therapy applications that typically required long, sustained expression, the irreversible nature of genome modification makes the transient delivery of genome-editing agents practical and desirable. While sufficient agent must be delivered to achieve a desired level of target locus modification, inducing the rapid disappearance of agent following a window of opportunity to effect on-target editing minimizes off-target modification. An integrated approach that leverages all three of these strategies, coupled with judicious choice of target site, currently offers the greatest chance of reducing undesired genome modification events to an extent comparable with or below the spontaneous mutation rate of healthy human cells.
The importance of reaching this goal will only increase as therapies based on programmable nucleases are developed. These therapies have the potential to modify nucleic acids within disease-affected cells and tissues to treat monogenic, highly penetrant diseases. A gain-of-function mutation, such as those found in the HTT gene in Huntington's disease and in the FGFR3 gene in achondroplasia could be treated through targeted cleavage of the mutant allele and disruption via NHEJ (Cox et al., 2015) . Some gain-of-function mutations such as the SOD1 G93A mutation found in some individuals with amyotrophic lateral sclerosis, being only a single mutation away from the wild-type allele, will require very precise nucleases to correct the mutant allele without disrupting the wild-type allele (Cox et al., 2015) . Limiting the activity of the nuclease to only the minimal amount of time needed to effect a therapeutic level of editing and, in some cases, to only the cell types needed to correct the mutation may be crucial. Chemical biology principles will also be critical to ensure efficient delivery and activity in the correct cell type. In vivo gene editing still suffers from a relatively limited number of efficient delivery systems, and current systems such as viral delivery and protein delivery via cationic lipids have shown different efficiencies in different cell types (Pajusola et al., 2002; Zuris et al., 2015) . Beyond human therapeutics, increased specificity and spatiotemporal control could also advance other applications of programmable nuclease such as those in agriculture (Belhaj et al., 2015; Voytas and Gao, 2014; Xie et al., 2015) and synthetic biology (Kiani et al., 2014; Liu et al., 2014b; Nielsen and Voigt, 2014; Nissim et al., 2014) .
Near-term developments will likely create even more specific genome-editing proteins, more broadly applicable proteins that can be used to target an even wider range of loci (e.g., by modifying the PAM requirement of Cas9; Kleinstiver et al., 2015) , the identification and characterization of new CRISPR systems with diverse properties (Ran et al., 2015; Shmakov et al., 2015; Zetsche et al., 2015a) , genome-editing proteins that respond to cell state or cell type, and programmable genome modifiers with new, more sophisticated functions beyond DNA cleavage and modulation of gene expression. These and other innovations in the field will bring genome editing increasingly toward a future in which tailor-made proteins mediate molecular surgery on genomes efficiently, precisely, and with no modification of undesired sequences or cells. Such a future would represent a transformative advance both for the life sciences and for medicine. 
